Biography
Dr. Joseph Levitt specializes in the treatment of adult pulmonary diseases including COPD, asthma, bronchiectasis, chronic cough, sarcoidosis, and pulmonary infections. He has practiced pulmonary medicine for more than 10 years. In addition to outpatient pulmonary medicine, Dr. Levitt is a critical care intensivist with a specific research interest in the clinical management of the Acute Respiratory Distress Syndrome (ARDS).
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Pulmonary Disease (2024)
- Board Certification: American Board of Internal Medicine, Critical Care Medicine (2024)
- Residency: University of Chicago Hospitals Internal Medicine Residency (2001) IL
-
- Medical Education: University of Minnesota School of Medicine (1998) MN
- Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2005) CA
- Fellowship: University of Chicago Pulmonary Disease and Critical Care Medicine Fellowship (2004) IL
- Internship: University of Arizona Internal Medicine Residency (1999) AZ
- Residency: John H Stroger Jr Hospital of Cook County Internal Medicine Residency (2002) IL
- M.D., University of Minnesota (1998)
Administrative Appointments
- Program Director, Division of Pulmonary and Critical Care Medicine, Stanford University Department of Medicine (2015 - Present)
-
Publications
-
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF
LEVITT, J., & Gould, M. K. (2005). Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 172(9), 1228–29. -
Treatment of acute lung injury: Historical perspective and potential future therapies
Levitt, J. E., & Matthay, M. A. (2006). Treatment of acute lung injury: Historical perspective and potential future therapies. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 27(4), 426–37. -
Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients
Vinayak, A. G., Levitt, J., Gehlbach, B., Pohlman, A. S., Hall, J. B., & Kress, J. P. (2006). Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients. ARCHIVES OF INTERNAL MEDICINE, 166(19), 2132–37. -
-
Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease
Kress, J. P., Vinayak, A. G., Levitt, J., Schweickert, W. D., Gehlbach, B. K., Zimmerman, F., … Hall, J. B. (2007). Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease. CRITICAL CARE MEDICINE, 35(2), 365–371. -
Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study
Levitt, J. E., Vinayak, A. G., Gehlbach, B. K., Pohlman, A., Van Cleve, W., Hall, J. B., & Kress, J. P. (2008). Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. CRITICAL CARE, 12(1). -
Randomized clinical trial of activated protein C for the treatment of acute lung injury
Liu, K. D., Levitt, J., Zhuo, H., Kallet, R. H., Brady, S., Steingrub, J., … Matthay, M. A. (2008). Randomized clinical trial of activated protein C for the treatment of acute lung injury. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 178(6), 618–23. -
Identification of Early Acute Lung Injury at Initial Evaluation in an Acute Care Setting Prior to the Onset of Respiratory Failure
Levitt, J. E., Bedi, H., Calfee, C. S., Gould, M. K., & Matthay, M. A. (2009). Identification of Early Acute Lung Injury at Initial Evaluation in an Acute Care Setting Prior to the Onset of Respiratory Failure. CHEST, 135(4), 936–43. -
The pathogenetic and prognostic value of biologic markers in acute lung injury.
Levitt, J. E., Gould, M. K., Ware, L. B., & Matthay, M. A. (2009). The pathogenetic and prognostic value of biologic markers in acute lung injury. Journal of Intensive Care Medicine, 24(3), 151–167. -
Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization?
Khazeni, N., & Levitt, J. E. (2009). Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization? AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 180(2), 191–92. -
Impact of Hepatitis B Core Antibody Positive Donors in Lung and Heart-Lung Transplantation: An Analysis of the United Network for Organ Sharing Database
Dhillon, G. S., Levitt, J., Mallidi, H., Valentine, V. G., Gupta, M. R., Sista, R., & Weill, D. (2009). Impact of Hepatitis B Core Antibody Positive Donors in Lung and Heart-Lung Transplantation: An Analysis of the United Network for Organ Sharing Database. TRANSPLANTATION, 88(6), 842–46. -
The utility of clinical predictors of acute lung injury: towards prevention and earlier recognition.
Levitt, J. E., & Matthay, M. A. (2010). The utility of clinical predictors of acute lung injury: towards prevention and earlier recognition. Expert Review of Respiratory Medicine, 4(6), 785–797. -
Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients
Dhillon, G. S., Valentine, V. G., Levitt, J., Patel, P., Gupta, M. R., Duncan, S. R., … Weill, D. (2012). Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. CLINICAL TRANSPLANTATION, 26(1), 105–10. -
PATIENT-RELATED FACTORS ASSOCIATED WITH HOSPITAL DISCHARGE TO A CARE FACILITY AFTER CRITICAL ILLNESS
Gehlbach, B. K., Salamanca, V. R., Levitt, J. E., Sachs, G. A., Sweeney, M. K., Pohlman, A. S., … Hall, J. B. (2011). PATIENT-RELATED FACTORS ASSOCIATED WITH HOSPITAL DISCHARGE TO A CARE FACILITY AFTER CRITICAL ILLNESS. AMERICAN JOURNAL OF CRITICAL CARE, 20(5), 378–386. -
Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure
Levitt, J. E., & Matthay, M. A. (2012). Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure. CRITICAL CARE, 16(3). -
Early acute lung injury: criteria for identifying lung injury prior to the need for positive pressure ventilation*.
Levitt, J. E., Calfee, C. S., Goldstein, B. A., Vojnik, R., & Matthay, M. A. (2013). Early acute lung injury: criteria for identifying lung injury prior to the need for positive pressure ventilation*. Critical Care Medicine, 41(8), 1929–37. -
Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials
Agrawal, A., Zhuo, H., Brady, S., Levitt, J., Steingrub, J., Siegel, M. D., … Liu, K. D. (2012). Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 303(8), L634–L639. -
Designing a better "nest": applicable to preventing hospital exposures to risk factors for acute respiratory distress syndrome or just retrospective study design?
Levitt, J. (2014). Designing a better "nest": applicable to preventing hospital exposures to risk factors for acute respiratory distress syndrome or just retrospective study design? Critical Care Medicine, 42(1), 197–198. -
Increased Resource Use in Lung Transplant Admissions in the Lung Allocation Score Era
Maxwelll, B. G., Mooney, J. J., Lee, P. H. U., Levitt, J. E., Chhatwani, L., Nicolls, M. R., … Dhillon, G. S. (2015). Increased Resource Use in Lung Transplant Admissions in the Lung Allocation Score Era. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 191(3), 302–8. -
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome
Liu, K. D., Wilson, J. G., Zhuo, H., Caballero, L., McMillan, M. L., Fang, X., … Matthay, M. A. (2014). Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. ANNALS OF INTENSIVE CARE, 4. -
Evolving Epidemiology and Definitions of the Acute Respiratory Distress Syndrome and Early Acute Lung Injury
Sweatt, A. J., & Levitt, J. E. (2014). Evolving Epidemiology and Definitions of the Acute Respiratory Distress Syndrome and Early Acute Lung Injury. CLINICS IN CHEST MEDICINE, 35(4), 609-? -
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., … Matthay, M. A. (2015). Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. The Lancet. Respiratory Medicine, 3(1), 24–32. -
Evolving epidemiology and definitions of the acute respiratory distress syndrome and early acute lung injury.
Sweatt, A. J., & Levitt, J. E. (2014). Evolving epidemiology and definitions of the acute respiratory distress syndrome and early acute lung injury. Clinics in Chest Medicine, 35(4), 609–24. -
Emerging Pharmacological Therapies for Prevention and Early Treatment of Acute Lung Injury
Ortiz-Diaz, E., Festic, E., Gajic, O., & Levitt, J. E. (2013). Emerging Pharmacological Therapies for Prevention and Early Treatment of Acute Lung Injury. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 34(4), 448–58. -
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.
Liu, K. D., Wilson, J. G., Zhuo, H., Caballero, L., McMillan, M. L., Fang, X., … Matthay, M. A. (2014). Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Annals of Intensive Care, 4, 22-? -
Prehospital use of inhaled steroids and incidence of acute lung injury among patients at risk
Festic, E., Ortiz-Diaz, E., Lee, A., Li, G., Kor, D. J., Adebola, A., … Gajic, O. (2013). Prehospital use of inhaled steroids and incidence of acute lung injury among patients at risk. JOURNAL OF CRITICAL CARE, 28(6), 985–91. -
Proteomic study of acute respiratory distress syndrome: current knowledge and implications for drug development
Levitt, J. E., & Rogers, A. J. (2016). Proteomic study of acute respiratory distress syndrome: current knowledge and implications for drug development. EXPERT REVIEW OF PROTEOMICS, 13(5), 457–69. -
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome
Festic, E., Carr, G. E., Cartin-Ceba, R., Hinds, R. F., Banner-Goodspeed, V., Bansal, V., … Levitt, J. E. (2017). Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome. CRITICAL CARE MEDICINE, 45(5), 798–805. -
Effect of Rosuvastatin on Acute Kidney Injury in Sepsis-Associated Acute Respiratory Distress Syndrome.
Hsu, R. K., Truwit, J. D., Matthay, M. A., Levitt, J. E., Thompson, B. T., & Liu, K. D. (2018). Effect of Rosuvastatin on Acute Kidney Injury in Sepsis-Associated Acute Respiratory Distress Syndrome. Canadian Journal of Kidney Health and Disease, 5, 2054358118789158. -
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay, M. A., Calfee, C. S., Zhuo, H., Thompson, B. T., Wilson, J. G., Levitt, J. E., … Liu, K. D. (2018). Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. The Lancet. Respiratory Medicine. -
Relationship Between Laryngeal Sensation, Length of Intubation, and Aspiration in Patients with Acute Respiratory Failure.
Borders, J. C., Fink, D., Levitt, J. E., McKeehan, J., McNally, E., Rubio, A., … Krisciunas, G. P. (2019). Relationship Between Laryngeal Sensation, Length of Intubation, and Aspiration in Patients with Acute Respiratory Failure. Dysphagia. -
Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-FIO2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome A Randomized Clinical Trial
Beitler, J. R., Sarge, T., Banner-Goodspeed, V. M., Gong, M. N., Cook, D., Novack, V., … Schoenfeld, D. (2019). Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-FIO2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome A Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321(9), 846–57. -
OXYGEN SATURATION TO FRACTION OF INSPIRED OXYGEN RATIO ON ADMISSION IS A PREDICTOR OF ARDS DEVELOPMENT AMONG PATIENTS AT RISK
Festic, E., Levitt, J., Kor, D., & Gajic, O. (2012). OXYGEN SATURATION TO FRACTION OF INSPIRED OXYGEN RATIO ON ADMISSION IS A PREDICTOR OF ARDS DEVELOPMENT AMONG PATIENTS AT RISK. CRITICAL CARE MEDICINE, 40(12), U176. -
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
Matthay, M. A., Calfee, C. S., Zhuo, H., Thompson, B. T., Wilson, J. G., Levitt, J. E., … Liu, K. D. (2019). Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. LANCET RESPIRATORY MEDICINE, 7(2), 154–62. -
Relationship Between Laryngeal Sensation, Length of Intubation, and Aspiration in Patients with Acute Respiratory Failure
Borders, J. C., Fink, D., Levitt, J. E., McKeehan, J., McNally, E., Rubio, A., … Krisciunas, G. P. (2019). Relationship Between Laryngeal Sensation, Length of Intubation, and Aspiration in Patients with Acute Respiratory Failure. DYSPHAGIA, 34(4), 521–28. -
Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients.
Ginde, A. A., Brower, R. G., Caterino, J. M., Finck, L., Banner-Goodspeed, V. M., Grissom, C. K., … Talmor, D. (2019). Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. The New England Journal of Medicine. -
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J. A., Asuni, A., … Rogers, A. J. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. -
Development of an accurate bedside swallowing evaluation decision tree algorithm for detecting aspiration in acute respiratory failure survivors.
Moss, M., White, S. D., Warner, H., Dvorkin, D., Fink, D., Gomez-Taborda, S., … Langmore, S. E. (2020). Development of an accurate bedside swallowing evaluation decision tree algorithm for detecting aspiration in acute respiratory failure survivors. Chest. -
Systemic and Inhaled Corticosteroids, with or without Beta Agonists, as Adjuvant Therapy in Community Acquired Pneumonia.
Helgeson, S. A., Levitt, J. E., & Festic, E. (2020). Systemic and Inhaled Corticosteroids, with or without Beta Agonists, as Adjuvant Therapy in Community Acquired Pneumonia. Acta Medica Academica, 49(1), 9–20. -
The Association Between Endotracheal Tube Size and Aspiration (During Flexible Endoscopic Evaluation of Swallowing) in Acute Respiratory Failure Survivors.
Krisciunas, G. P., Langmore, S. E., Gomez-Taborda, S., Fink, D., Levitt, J. E., McKeehan, J., … Moss, M. (2020). The Association Between Endotracheal Tube Size and Aspiration (During Flexible Endoscopic Evaluation of Swallowing) in Acute Respiratory Failure Survivors. Critical Care Medicine. -
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.
Flythe, J. E., Assimon, M. M., Tugman, M. J., Chang, E. H., Gupta, S., Shah, J., … Leaf, D. E. (2020). Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. -
Quantitative Assessment of Blood Lactate in Shock: Measure of Hypoxia or Beneficial Energy Source.
Levitt, D. G., Levitt, J. E., & Levitt, M. D. (2020). Quantitative Assessment of Blood Lactate in Shock: Measure of Hypoxia or Beneficial Energy Source. BioMed Research International, 2020, 2608318. -
Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure.
Langmore, S. E., Krisciunas, G. P., Warner, H., White, S. D., Dvorkin, D., Fink, D., … Moss, M. (2020). Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure. Dysphagia. -
Phenotypes and personalized medicine in the acute respiratory distress syndrome
Matthay, M. A., Arabi, Y. M., Siegel, E. R., Ware, L. B., Bos, L. D. J., Sinha, P., … Calfee, C. S. (2020). Phenotypes and personalized medicine in the acute respiratory distress syndrome. INTENSIVE CARE MEDICINE, 2136–52. -
The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design.
Levitt, J. E., Festic, E., Desai, M., Hedlin, H., Mahaffey, K. W., Rogers, A. J., … Matthay, M. A. (2021). The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design. Annals of the American Thoracic Society. -
Correction to: Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure.
Langmore, S. E., Krisciunas, G. P., Warner, H., White, S. D., Dvorkin, D., Fink, D., … Moss, M. (2021). Correction to: Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure. Dysphagia. -
Prospective validation of an 11-gene mRNA host response score for mortality risk stratification in the intensive care unit.
Moore, A. R., Roque, J., Shaller, B. T., Asuni, T., Remmel, M., Rawling, D., … Rogers, A. J. (2021). Prospective validation of an 11-gene mRNA host response score for mortality risk stratification in the intensive care unit. Scientific Reports, 11(1), 13062. -
The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial.
Bunning, B., Hedlin, H., Purington, N., Sundaram, V., Kapphahn, K., Weng, Y., … Desai, M. (2021). The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial. Contemporary Clinical Trials, 106509. -
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Goligher, E. C., Bradbury, C. A., McVerry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., … Zhong, Y. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England Journal of Medicine. -
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., … Zampieri, F. G. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England Journal of Medicine. -
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., … Patel, M. M. (2021). Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 70(34), 1156–1162. -
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021
Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., … Busse, L. W. (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 70(38), 1337–1343. -
Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
Lewis, N. M., Naioti, E. A., Self, W. H., Ginde, A. A., Douin, D. J., Talbot, H. K., … Tenforde, M. W. (1800). Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021. The Journal of Infectious Diseases. -
Promises and challenges of personalized medicine to guide ARDS therapy
Wick, K. D., McAuley, D. F., Levitt, J. E., Beitler, J. R., Annane, D., Riviello, E. D., … Matthay, M. A. (2021). Promises and challenges of personalized medicine to guide ARDS therapy. CRITICAL CARE, 25(1), 404. -
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021
Tenforde, M. W., Patel, M. M., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., … Self, W. H. (2022). Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 71(4), 118–124. -
Clinical trial design during and beyond the pandemic: the I-SPY COVID trial
Calfee, C. S., Liu, K. D., Asare, A. L., Beitler, J. R., Berger, P. A., Coleman, M. H., … Boerger, L. L. (2022). Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. NATURE MEDICINE, 28(1), 9–11. -
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
Files, D. C., Matthay, M. A., Calfee, C. S., Aggarwal, N. R., Asare, A. L., Beitler, J. R., … Liu, K. D. (2022). I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open, 12(6), e060664. -
Opportunities for improved clinical trial designs in acute respiratory distress syndrome.
Wick, K. D., Aggarwal, N. R., Curley, M. A., Fowler, A. A., Jaber, S., Kostrubiec, M., … Matthay, M. A. (2022). Opportunities for improved clinical trial designs in acute respiratory distress syndrome. The Lancet. Respiratory Medicine, 10(9), 916–924. -
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.
Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., … Self, W. H. (2022). Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ (Clinical Research Ed.), 379, e072065. -
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., … Self, W. H. (2022). Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. MMWR. Morbidity and Mortality Weekly Report, 71(42), 1327–1334. -
Opportunities for improved clinical trial designs in acute respiratory distress syndrome
Wick, K. D., Aggarwal, N. R., Curley, M. A. Q., Fowler, A. A., Jaber, S., Kostrubiec, M., … Matthay, M. A. (2022). Opportunities for improved clinical trial designs in acute respiratory distress syndrome. LANCET RESPIRATORY MEDICINE, 10(9), 916–924. -
Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.
Feng, A., Yang, E. Y., Moore, A. R., Dhingra, S., Chang, S. E., Yin, X., … Utz, P. J. (2023). Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness. JCI Insight, 8(3). -
Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials.
Pienkos, S. M., Moore, A. R., Guan, J., Levitt, J. E., Matthay, M. A., Baron, R. M., … Rogers, A. J. (2023). Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials. Critical Care (London, England), 27(1), 126. -
Evaluation of acebilustat, a selective inhibitor of leukotriene B4 biosynthesis, for treatment of outpatients with mild-moderate COVID-19 disease: A randomized, double-blind, placebo- controlled Phase 2 trial.
Levitt, J. E., Hedlin, H., Duong, S., Lu, D., Lee, J., Bunning, B., … Rogers, A. J. (2023). Evaluation of acebilustat, a selective inhibitor of leukotriene B4 biosynthesis, for treatment of outpatients with mild-moderate COVID-19 disease: A randomized, double-blind, placebo- controlled Phase 2 trial. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. -
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.
Self, W. H., Shotwell, M. S., Gibbs, K. W., de Wit, M., Files, D. C., Harkins, M., … Collins, S. P. (2023). Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA, 329(14), 1170–1182. -
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
Brown, S. M., Barkauskas, C. E., Grund, B., Sharma, S., Phillips, A. N., Leither, L., … Lane, H. C. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. The Lancet. Respiratory Medicine. -
Right Ventricular Dysfunction Patterns Among Patients with COVID-19 in the Intensive Care Unit - a Retrospective Cohort Analysis.
Sanchez, P. A., O'Donnell, C. T., Francisco, N., Santana, E. J., Moore, A. R., Pacheco-Navarro, A., … Rogers, A. J. (2023). Right Ventricular Dysfunction Patterns Among Patients with COVID-19 in the Intensive Care Unit - a Retrospective Cohort Analysis. Annals of the American Thoracic Society. -
Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials.
Moore, A. R., Pienkos, S. M., Sinha, P., Guan, J., O'Kane, C. M., Levitt, J. E., … Rogers, A. J. (2023). Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials. Critical Care Medicine. -
Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.
Feng, A., Yang, E., Moore, A., Dhingra, S., Chang, S., Yin, X., … Utz, P. (2022). Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections. Research Square. -
Association between emergency department disposition and mortality in patients with COVID-19 acute respiratory distress syndrome.
Lebold, K. M., Moore, A. R., Sanchez, P. A., Pacheco-Navarro, A. E., O'Donnell, C., Roque, J., … Wilson, J. G. (2024). Association between emergency department disposition and mortality in patients with COVID-19 acute respiratory distress syndrome. Journal of the American College of Emergency Physicians Open, 5(3), e13192.
-
Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Reevaluation Of Systemic Early Neuromuscular Blockade
- ACTIV-3: Therapeutics for Inpatients With COVID-19
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
- Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
- Statins for Acutely Injured Lungs From Sepsis
- EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
- Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
- LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Practice Locations
Chest Clinic in Palo Alto Stanford, CA
Stanford, CA
Chest Clinic in Palo Alto
300 Pasteur Dr, 1st Fl Rm A175
Stanford , CA 94305
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(50 reviews)
He's a good man I like him
He is an excellent doctor who has greatly changed how I live by 100%. He is through while being a good listener and showing concern.
Very personable good patient carring doctor. Thankful he referred me to the ER for more testing.
The doctor was kind listen explain everything gave good and comprehensive discussion I came to the appointment worried and anxious and left encouraged feeling much better
Dr. Levitt is an excellent Doctor, deserves much praise!
Dr. Levitt cared about about symptoms and had an good idea for further troubleshooting.
Dr. Levitt, took time with me in answering the many questions I had He was kind and showed me results that I did not have Cancer. He has been amazing in all aspects of my Medical care.
Dr Levitt took time to review my medical record, listen attentively to my concerns.
I have been a patient of Dr. Levitt for at least 10 years. He is an
outstanding Pulmonary physician.
In addition he is a very pleasant and friendly person.
Dr levitt is a excellent doctor 👨†⚕ï¸
Dr. levitt is an excellent listener and I appreciate that he encourages dialogue and discussion. His expertise, determination to find root causes of my breathing problems, plan of action to address my lung issues has taken me from being barely able to climb stairs to breathing well enough to exercise and enjoying an active life.
The techs and doctor were all excellent. Especially Dr. Levitt, who took his time to explain possible causes of my symtoms.
He is clear, cares about me and my health. I enjoy having visits with him. He makes me feel comfortable and I am able to freely talk with him.
I’m very happy with Dr Levitt
VERY, VERY GOOD experience.
Excellent.
Dr. Levitt explains my condition in terms I understand.
Very good care & service.
I really like Dr. Jonas. She is very caring!!!
Dr. Joseph Levitt is a very compassionate & kind dr.
Recommend everyone.
He is the most attentive & compassionate doctor! I was very impressed!
Very good experience.
I feel well cared for always in this clinic though I have seen multiple fellows & attendings they pay attention and have thoughtful opinions.
Everyone was so helpful & considerate.
Dr. Levitt was very understanding of my feeling. He also took time for me not in a hurry. Overall experience was excellent.
Dr. Joseph Levitt is an excellent doctor. He took time to review my medical history. Listen to my description of my symptoms and problems, explained my illness, recommended treatments. Very good care!
One of the best doctors around.
Really appreciate & like Dr. Levitt.
Dr. Levitt was generous with his time and knowledge. He even called me after the visit with more insight after seeing a CT CD. I'm very pleased.
Dr. Levitt is an outstanding physician.
I really appreciate that Dr. Levitt never makes me feel rushed. He answers all my questions & gives me as much time as I need.
He was very nice, took me when I came in quickly.
Dr. Levitt is great.
Dr. Nils Nickel has been committed to understanding my diagnosis and the best approach to understanding how the symptoms are related. Dr. Levitt became involved in my case this month, and both Dr. Nickel & Dr. Levitt have worked together to provide exceptional care and support. I am truly grateful to be under their care.
My communication with Dr. Levitt was pleasant & easy. I am looking forward to be in his care and I am left with clear understanding of my problems.
Very satisfied.
Dr. Levitt is a friendly, thorough and excellent doctor.
They attention was "VERY GOOD."
Dr. Levitt is the bet!!! I took the time to fill this out because I feel Dr. Levitt's professional & personal attention far exceeds anyone else.
Dr. Levitt is an outstanding doctor.
Personally involved feeling kind of doctor & staff!
Very very good.
Doctor was very caring provided all the information I needed. I have to pulmonologist who referred me that I would highly recommend doctor.
Constantly good; concerned; knowledgeable; gives more than 100%.
Dr. Levitt & staff are excellent.
Everything was very good.
Always confident of service.
Sorry there was no excellent col. to check.
Dr. Levitt is not my regular pulmonologist, but he did an excellent job at explaining the MRI and the treatment device he gave me.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records